A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Hengrui Medicine

Status and phase

Withdrawn

Phase 3

Conditions

Chemotherapy-Induced Thrombocytopenia

Treatments

Drug: Hetrombopag

Drug: Matching placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05261646

HR-TPO-CIT-301

Details and patient eligibility

About

The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of chemotherapy regimen (i.e., delayed start, dose reduction, omission, or discontinuation) because of thrombocytopenia [platelet count <100×109/L], to determine an optimal dose of hetrombopag and to demonstrate its superiority over placebo.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female gender, age ≥18 years.
Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma [NSCLC], breast, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer).
Receiving a chemotherapy cycle of 21 days with one or more of the following chemotherapeutic drugs:
- Antimetabolites, including gemcitabine, etc.
- Platinum-based agents, including carboplatin, nedaplatin, cisplatin, and lobaplatin, etc.
- Anthracyclines, including doxorubicin, daunorubicin, epirubicin, etc.
- Alkylating agents, including cyclophosphamide, ifosfamide, etc.
Delay for at least 1 week from the scheduled chemotherapy cycle because of thrombocytopenia (PC <75×109/L for 4 weeks after the start of the previous chemotherapy cycle.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Expected survival ≥ 6 months at screening.
At least 2 remaining chemotherapy cycles with current chemotherapy regimen.
Agreement for subjects of childbearing potential to take effective contraceptive measures throughout the study (including male or female condoms, contraceptive foam, contraceptive gel, contraceptive diaphragm, contraceptive cream, contraceptive suppository, abstinence, and inserted intrauterine devices, etc.); except female subjects who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation or have been in menopause for more than 1 year, and male subjects who have undergone bilateral vasectomy or ligation.
Signed ICF for voluntary participation in the study and good compliance.

Exclusion criteria

PC <25×109/L or ≥75 x 109/L at screening or enrollment.
Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).
Hematologic malignancies.
Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months before screening.
Intracranial metastases or disease.
Bone marrow involvement or bone marrow metastasis on routine imaging.
Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).
Pelvic, spinal radiotherapy, or large-field bone radiation received within 3 months prior to screening.
Severe cardiovascular disorders or interventions within 6 months before screening: New York Heart Association (NYHA) Class III-IV; arrhythmias known to increase the risk of thromboembolism (e.g., atrial fibrillation); prolonged QTc (>450 msec for males and >460 msec for females); coronary artery angioplasty, stenting, or bypass grafting.
Any arterial or venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism, transient ischemic attack/stroke, or myocardial infarction) within 6 months prior to screening.
Known bleeding disorders, platelet dysfunction.
Use of anticoagulants or non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days of screening. The use of low dose aspirin (81 mg) is allowed.
Severe hemorrhage (e.g., gastrointestinal, or intracranial hemorrhage) within 2 weeks before screening.
Absolute neutrophil count (ANC) <1.5× 109/L, or Hb <80 g/L. Use of granulocyte colony stimulating factor, red blood cell, or erythropoietin infusion therapy that meets routine clinical practice is allowed.
Significantly abnormal liver function:
- For subjects without liver metastasis: alanine aminotransferase/aspartate aminotransferase (ALT/AST) > 3 × ULN (upper limit of normal), TBL > 3 × ULN.
- For subjects with liver metastases: ALT/AST ≥ 5 × ULN, TBL > 3 × ULN.
Abnormal renal function: estimated glomerular filtration rate (eGFR) ≤ 60 mL/min (Cockcroft-Gault estimated creatinine clearance).
Previous treatments with TPO-R agonists (e.g., eltrombopag, romiplostim) at any time before screening or enrollment.
Platelet transfusion received within 72 hours prior to screening or enrollment, with PC >75×109/L at screening or enrollment.
Known or expected allergy or intolerance to the active substances or excipients of hetrombopag.
Acute or chronic hepatitis C or hepatitis B.
Human immunodeficiency virus (HIV) infection.
Confirmed SARS-CoV-2 (COVID-19) infection (validated test positive), or suspected COVID-19 infection (clinical symptoms without documented test results) within 4 weeks before screening, or close contact with a person with known or suspected COVID-19 infection within 2 weeks before screening (subject may be included with a documented negative result for a validated COVID-19 test).
Pregnancy/intention to become pregnant during the study period or lactation.
Participation in another clinical trial within 30 days or 5 half-lives of an investigational product (whichever is longer) prior to screening.
Investigator's judgement that participation in the study creates a significant risk for the health of a subject, or his/her condition may affect evaluation of the safety and/or efficacy of hetrombopag.